2,623 reports of this reaction
1.9% of all NIVOLUMAB reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for NIVOLUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 2,623 FDA adverse event reports linking NIVOLUMAB to DYSPNOEA. This represents approximately 1.9% of all 139,909 adverse event reports for this drug.
NIVOLUMAB has an overall safety score of 89 out of 100. Patients taking NIVOLUMAB who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for NIVOLUMAB, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for NIVOLUMAB:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,623 FDA reports for NIVOLUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.9% of all adverse event reports for NIVOLUMAB, making it a notable side effect.
If you experience dyspnoea while taking NIVOLUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.